Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 6/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | FDPS | P14324 | 1/20 | 0.46 |
| ▸ | LSS | P48449 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3367242 | 0.89 | PGR (0.52) | L3MBTL1MEN1KMT2AFDPSLSS | |
| SCHEMBL3364934 | 0.89 | FFAR1 (0.52) | L3MBTL1ALDH1A1LTA4HMEN1KMT2A | |
| SCHEMBL3363397 | 0.89 | LSS (0.58) | L3MBTL1ALDH1A1LTA4HHPGDLSS | |
| SCHEMBL7704534 | 0.88 | L3MBTL1 (0.66) | L3MBTL1ALDH1A1LTA4HMEN1KMT2A | |
| SCHEMBL3366906 | 0.86 | LSS (0.56) | L3MBTL1HPGDLSSTDP1 | |
| SCHEMBL3365335 | 0.84 | LSS (0.62) | L3MBTL1ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL7165354 | 0.83 | L3MBTL1 (0.54) | L3MBTL1MEN1KMT2ATSHRPGR | |
| SCHEMBL3368340 | 0.78 | FFAR1 (0.53) | L3MBTL1LTA4HMEN1KMT2AFDPS | |
| SCHEMBL3367350 | 0.78 | FFAR1 (0.53) | L3MBTL1LTA4HMEN1KMT2AFDPS | |
| SCHEMBL3368819 | 0.78 | LSS (0.51) | L3MBTL1MEN1KMT2ALSSTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020038025-A1 | Analine derivatives as OSC inhibitors | F.HOFFMANN-LA ROCHE AG (CH) | 2002-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020038025-A1 | Analine derivatives as OSC inhibitors | LSS, CYP51A1, CYP46A1 | L3MBTL1 1316/4885ALDH1A1 864/4885LTA4H 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.